Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
The quarter in numbers
Iambic Therapeutics reported third-quarter 2026 collaboration revenue of $11.4 million ($11,351 thousand), against $4.7 million a year earlier. The company said the increase was primarily due to its discovery collaborations. The release excerpt shows no product sales.
Total operating expenses were $41.5 million, up from $27.3 million, leaving a loss from operations of $30.1 million versus $22.6 million. Net loss was $38.5 million, compared with $21.5 million in Q3 2025, or $(8.52) per share versus $(5.24). The per-share figures rest on 4,521,229 weighted-average shares, a count that predates the October IPO.
Net loss included a $10.4 million non-cash charge for the change in fair value of convertible notes. The company said the notes converted into common stock immediately before the IPO closed. By our arithmetic, excluding that charge, the net loss would be about $28.1 million. Interest income was $2.0 million, up from $1.2 million.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Iambic Therapeutics, Inc.: quarterly results release (SEC filing) SEC EDGAR · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.
Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3
Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.